Dr. John Cush RheumNow
4 years ago
Causes of Death in Lupus
The California Lupus Surveillance Project has longitudinally followed included SLE cases and shown that overall, the leading cause of death was CVD, followed by rheumatic disease and hematologic/oncologic conditions.
https://t.co/XRtD2Rr77j https://t.co/fzVGSeQGQu
Dr. John Cush RheumNow
4 years ago
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/sR2OMNtxAk https://t.co/qOdMEZheFz
Dr. John Cush RheumNow
4 years ago
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/eHKx2D0kKp https://t.co/UdC0k3hlmX
Dr. John Cush RheumNow
4 years ago
20% of SLE pregnancies end w/ adverse preg outcome (APO). Use of LASSO & Machine learning of PROMISSE data (385 pt) before wk 12 could predict APO based on BP Meds, low Plts, Dz activity, and LAC (AUC=0.78) https://t.co/DZJ9UCpwCk https://t.co/5yYgj9g0dP
Dr. John Cush RheumNow
4 years ago
Physician Burnout Rising
The NY Times has reported results of a study showing that nearly 2/3 of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic.
https://t.co/EGDezgyQ9e https://t.co/TmG01Un191
Dr. John Cush RheumNow
4 years ago
Rheumatology Salaries and Career Choices
A recent doximity report shows how rheumatology salaries increase by years in practice.
https://t.co/Fmzq5zv3yp https://t.co/5Ju7ABiK2m
Dr. John Cush RheumNow
4 years ago
Opioid Crisis Costs USA $1.5 Trillion
Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.
https://t.co/n2FC75hpDt https://t.co/UHTOMUDP5Q
Dr. John Cush RheumNow
4 years ago
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/Vt25ui8GwF https://t.co/chKZt6dvaO
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Dr. John Cush RheumNow
4 years ago
Microbioime analyses of cancer patients suggests over abundance of fungi, expecially transcriptionally active Candida and is associated with gastrointestinal and lung cancers.
Candida DNA is also predictive of reduced survival in GI cancers https://t.co/JKaffWZqy7 https://t.co/suByUP6anA
The NY Times has reported results of a study showing that nearly two-thirds of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic. These findings suggest that burnout rates amongst US doctors have risen to alarming levels.
A recent doximity report shows how rheumatology salaries increase by years in practice. Their salary estimates are based on Doximity acquired data from over 200,000 physicians, along with publicly-available career and salary data from the U.S. Bureau of Labor Statistics, the U.S. Census. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience.
Dr. John Cush RheumNow
4 years ago
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/pps1Du9rEt https://t.co/ZEDiHwZ5po

